Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Buenos dias! Writing from one of the more unique locations in my tenure as a Readout author…. Hola from a mercado in Mexico City. On tap today: Early studies show that checkpoint inhibitors may be more effective if combined with JAK inhibitors. Also, more promising anti-obesity results and perhaps a more potent PrEP for HIV.
Sarepta gene therapy approved for most Duchenne patients
The FDA yesterday dramatically expanded its approval for Elevidys, a gene therapy for Duchenne muscular dystrophy, authorizing access for nearly all patients with the fatal muscle-wasting disease.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect